News Releases
View printer-friendly version < < backNEW BRUNSWICK, N.J., Jan 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced sales for the year 2008 of $63.7 billion, an increase of 4.3% over 2007. Operational growth was 1.9% with currency contributing 2.4%. Domestic sales decreased 0.4%, while international sales increased 9.7%, reflecting operational growth of 4.6% and a positive currency impact of 5.1%. Worldwide sales in the fourth quarter of 2008 were $15.2 billion, a decrease of 4.9% as compared to the fourth quarter of 2007. Operational results declined 1.0% and the negative impact of currency was 3.9%. Domestic sales decreased 6.9%, while international sales decreased 2.7%, reflecting operational growth of 5.4% and a negative currency impact of 8.1%.
Net earnings and diluted earnings per share for the year 2008 were $12.9 billion and $4.57. Full-year 2008 net earnings included special items related to in-process research and development charges of $181 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation settlements in the fourth quarter. Full-year 2007 net earnings included special items related to an in-process research and development charge of $807 million with no tax benefit, an after-tax charge of $528 million for restructuring, an after-tax non-cash charge of $441 million for the NATRECOR intangible asset write-down, and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. Excluding these special items, net earnings for 2008 were $12.9 billion and earnings per share were $4.55, representing increases of 6.8% and 9.6%, respectively, as compared with the same period in 2007. *
Net earnings and diluted earnings per share for the fourth quarter of 2008 were $2.7 billion and $0.97, respectively. Fourth quarter 2008 net earnings included special items related to in-process research and development charges of $141 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation settlements. Fourth quarter 2007 net earnings included special items related to an after-tax non-cash charge of $441 million for the NATRECOR asset write-down and a tax gain of $267 million associated with the restructuring of certain international subsidiaries. Excluding these special items, net earnings for the current quarter were $2.6 billion and diluted earnings per share were $0.94, representing increases of 3.1% and 6.8%, respectively, as compared to the same period in 2007. *
The Company announced earnings guidance for full-year 2009 of $4.45 to $4.55 per share, which excludes the impact of special items. This guidance includes anticipated dilution of $.03 to $.05 from the acquisition of Mentor Corporation, which is expected to close in January 2009.
"I am extremely proud of Johnson & Johnson's accomplishments in 2008 and the way our people met our commitments," said William C. Weldon, Chairman and Chief Executive Officer. "We delivered solid earnings growth and made significant progress in our research pipelines while continuing to invest in the future growth of our business. I am confident that we are well positioned for continued leadership and growth in health care."
The Worldwide Consumer segment achieved annual sales in 2008 of $16.0 billion, an increase of 10.8% over the prior year with operational growth of 8.3% and a positive impact from currency of 2.5%. Domestic sales increased 8.3%, while international sales increased 12.8% (8.3% from operations and 4.5% from currency).
Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; the skin care lines of NEUTROGENA, AVEENO and CLEAN & CLEAR; international sales of Baby Care products; and LISTERINE antiseptic mouthrinse. Also contributing to growth were sales from the recently completed acquisition of DABAO, the leading moisturizer in China.
Worldwide Pharmaceutical sales of $24.6 billion for the full-year 2008 represented a decrease of 1.2% versus the prior year with a decline of 3.1% operationally and a positive impact from currency of 1.9%. Domestic sales decreased 4.9%, while international sales increased 5.1% (0.1% from operations and 5.0% from currency).
Sales results reflect the strong performance of VELCADE, a treatment for multiple myeloma; REMICADE, a biologic approved for the treatment of a number of immune mediated inflammatory diseases; RISPERDAL CONSTA, an antipsychotic medication; and TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches. Sales results of RISPERDAL, an antipsychotic medication, were negatively impacted by generic competition and sales of PROCRIT, a product for the treatment of anemia, were lower due to a decline in the market.
During the quarter, the Company announced that the U.S. Food and Drug Administration (FDA) approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults 18 years of age or older. In addition, the Company submitted two New Drug Applications to the FDA: trabectedin (known as YONDELIS outside the U.S.) when administered in combination with DOXIL for the treatment of women with relapsed ovarian cancer and carisbamate, a new investigational compound for the adjunctive treatment of partial onset seizures in patients 16 years of age and older. The FDA also granted PREZISTA, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults and traditional approval as twice-daily for use in treatment-experienced adult patients. Outside the United States, the European Commission granted full approval of the Marketing Authorization of PREZISTA in combination with ritonavir and other antiretroviral medicinal products for the treatment of HIV-1 infection, and extended the indication to include all treatment-experienced adult patients.
Worldwide, the Medical Devices and Diagnostics segment achieved annual sales of $23.1 billion in 2008, representing an increase over the prior year of 6.4% with operational growth of 3.5% and a positive currency impact of 2.9%. Domestic sales increased 1.0%, while international sales increased 11.3% (5.8% from operations and 5.5% from currency).
Primary contributors to the operational growth included Ethicon Endo-Surgery's minimally invasive products; Vistakon's disposable contact lenses; and DePuy's orthopaedic joint reconstruction and sports medicine businesses. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market.
During the quarter, the Company completed the acquisition of SurgRx, Inc., a privately held developer of the advanced bipolar tissue sealing system used in the ENSEAL family of devices, and the divestiture of Ethicon's Professional Wound Care business to One Equity Partners. In addition, the Company completed the acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products.
Also in the quarter, the Company entered into a definitive agreement to acquire Mentor Corporation, a leading supplier of medical products for the global aesthetic market.
The Company also announced 510(k) clearance from the FDA for the VITROS 5600 Integrated System, a next generation system uniquely designed to integrate clinical chemistry and immunoassay testing to increase laboratory productivity, and the VITROS 3600 Immunodiagnostic System, a new high-capacity system which combines accuracy and efficiency with a broad menu of immunoassays.
As an initial step in the creation of a wellness and prevention business platform, the Company completed two acquisitions during the quarter: HealthMedia, Inc., a privately held company that creates web-based behavior change interventions, and LGE Performance Systems, Inc., a privately held company known as Human Performance Institute, which develops science-based training programs to improve employee engagement and productivity.
About Johnson & Johnson
Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges and restructuring charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at www.jnj.com.
Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, sales of key products/franchises and a pharmaceutical pipeline of selected compounds in late stage development. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) FOURTH QUARTER
-------------------------------- --------------
Percent Change
--------------
2008 2007 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $1,655 1,626 1.8% 1.8 -
International 2,200 2,184 0.7 10.6 (9.9)
--------------- ----- ----- --- ---- ----
3,855 3,810 1.2 6.9 (5.7)
----- ----- --- --- ----
Pharmaceutical
U.S. 3,430 3,944 (13.0) (13.0) -
International 2,255 2,453 (8.1) 0.5 (8.6)
-------------- ----- ----- ---- --- ----
5,685 6,397 (11.1) (7.8) (3.3)
----- ----- ----- ---- ----
Med Devices & Diagnostics
U.S. 2,582 2,661 (3.0) (3.0) -
International 3,060 3,089 (0.9) 5.6 (6.5)
-------------- ----- ----- ---- --- ----
5,642 5,750 (1.9) 1.6 (3.5)
----- ----- ---- --- ----
U.S. 7,667 8,231 (6.9) (6.9) -
International 7,515 7,726 (2.7) 5.4 (8.1)
------------- ----- ----- ---- --- ----
Worldwide $15,182 15,957 (4.9)% (1.0) (3.9)
--------- ------- ------ ---- ---- ----
(Unaudited; Dollars in Millions) TWELVE MONTHS
-------------------------------- -------------
Percent Change
--------------
2008 2007 Total Operations Currency
--------------------- ---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $6,937 6,408 8.3% 8.3 -
International 9,117 8,085 12.8 8.3 4.5
--------------- ----- ----- ---- --- ---
16,054 14,493 10.8 8.3 2.5
------ ------ ---- --- ---
Pharmaceutical
U.S. 14,831 15,603 (4.9) (4.9) -
International 9,736 9,263 5.1 0.1 5.0
-------------- ----- ----- --- --- ---
24,567 24,866 (1.2) (3.1) 1.9
------ ------ ---- ---- ---
Med Devices & Diagnostics
U.S. 10,541 10,433 1.0 1.0 -
International 12,585 11,303 11.3 5.8 5.5
-------------- ------ ------ ---- --- ---
23,126 21,736 6.4 3.5 2.9
------ ------ --- --- ---
U.S. 32,309 32,444 (0.4) (0.4) -
International 31,438 28,651 9.7 4.6 5.1
------------- ------ ------ --- --- ---
Worldwide $63,747 61,095 4.3% 1.9 2.4
--------- ------- ------ --- --- ---
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited; Dollars in Millions) FOURTH QUARTER
-------------------------------- --------------
Percent Change
--------------
2008 2007 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers
by geographic area
U.S. $7,667 8,231 (6.9)% (6.9) -
---- ------ ----- ---- ---- ---
Europe 3,851 4,159 (7.4) 2.7 (10.1)
Western Hemisphere
excluding U.S. 1,187 1,309 (9.3) 6.0 (15.3)
Asia-Pacific,
Africa 2,477 2,258 9.7 9.9 (0.2)
------------- ----- ----- --- --- ----
International 7,515 7,726 (2.7) 5.4 (8.1)
------------- ----- ----- ---- --- ----
Worldwide $15,182 15,957 (4.9)% (1.0) (3.9)
--------- ------- ------ ---- ---- ----
TWELVE MONTHS
-------------
Percent Change
--------------
2008 2007 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers
by geographic area
U.S. $32,309 32,444 (0.4)% (0.4) -
---- ------- ------ ---- ---- ---
Europe 16,782 15,644 7.3 1.8 5.5
Western Hemisphere
excluding U.S. 5,173 4,681 10.5 7.7 2.8
Asia-Pacific,
Africa 9,483 8,326 13.9 8.4 5.5
------------- ----- ----- ---- --- ---
International 31,438 28,651 9.7 4.6 5.1
------------- ------ ------ --- --- ---
Worldwide $63,747 61,095 4.3% 1.9 2.4
--------- ------- ------ --- --- ---
Johnson & Johnson and Subsidiaries
-----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) FOURTH QUARTER
------------------------------ --------------
2008 2007
------------------ -------------------- Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
------------------ ------ -------- ------ -------- ---------
Sales to customers $15,182 100.0 $15,957 100.0 (4.9)
------------------ ------- ----- ------- ----- ----
Cost of products
sold 4,372 28.8 4,734 29.7 (7.6)
Selling,
marketing and
administrative
expenses 5,665 37.3 5,721 35.8 (1.0)
Research expense 2,108 13.9 2,328 14.6 (9.5)
In-process research
& development
(IPR&D) 141 0.9 - -
Restructuring expense - - - -
Interest (income)
expense, net 17 0.1 (35) (0.2)
Other (income)
expense, net (638) (4.2) 877 5.5
--------------------- ---- ---- --- --- ----
Earnings before
provision for taxes
on income 3,517 23.2 2,332 14.6 50.8
Provision for taxes on
income 803 5.3 (42) (0.3) NM*
---------------------- --- --- --- ---- --
Net earnings $2,714 17.9 $2,374 14.9 14.3
------------ ------ ---- ------ ---- ----
Net earnings per
share (Diluted) $0.97 $0.82 18.3
Average shares
outstanding
(Diluted) 2,801.6 2,889.2
Effective tax rate 22.8% (1.8)%
------------------
Adjusted earnings
before provision
for taxes and net
earnings
Earnings before
provision for
taxes on
income $3,279 (1) 21.6 $3,010 (2) 18.9 8.9
Net earnings $2,626 (1) 17.3 $2,548 (2) 16.0 3.1
Net earnings per
share (Diluted) $0.94 (1) $0.88 (2) 6.8
Effective tax rate 19.9% 15.3%
-------------------- ---- ----
(1) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings per
share (diluted) is the exclusion of IPR&D of $141 million with no tax
benefit and $0.05 per share, respectively and the exclusion of income
representing the net impact of litigation settlements of $379 million,
$229 million, and $0.08 per share, respectively.
(2) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings per
share (diluted) is the exclusion of the NATRECOR(R) intangible asset
write-down of $678 million, $441 million, and $0.15 per share,
respectively, and the exclusion of an international tax gain on
restructuring of $267 million on net earnings, and $0.09 per share.
*Not meaningful
Johnson & Johnson and Subsidiaries
-----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions
Except Per Share Figures) TWELVE MONTHS
-------------------------- -------------
2008 2007
------------------ ------------------ Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
------------------ ------ -------- ------ -------- ---------
Sales to customers $63,747 100.0 $61,095 100.0 4.3
------------------ ------- ----- ------- ----- ---
Cost of products
sold 18,511 29.1 17,751 29.1 4.3
Selling, marketing
and administrative
expenses 21,490 33.7 20,451 33.5 5.1
Research expense 7,577 11.9 7,680 12.6 (1.3)
In-process research
& development
(IPR&D) 181 0.3 807 1.3
Restructuring expense - - 745 1.2
Interest
(income)expense, net 74 0.1 (156) (0.3)
Other (income)
expense, net (1,015) (1.6) 534 0.9
------------------- ------ ---- --- --- ----
Earnings before
provision for taxes
on income 16,929 26.5 13,283 21.7 27.4
Provision for taxes
on income 3,980 6.2 2,707 4.4 47.0
-------------------- ----- --- ----- --- ----
Net earnings $12,949 20.3 $10,576 17.3 22.4
------------ ------- ---- ------- ---- ----
Net earnings per
share (Diluted) $4.57 $3.63 25.9
Average shares
outstanding
(Diluted) 2,835.6 2,910.7
Effective tax rate 23.5% 20.4%
-----------------------
Adjusted earnings
before provision for
taxes and net earnings
Earnings before
provision for taxes
on income $16,731 (1) 26.2 $15,513 (2) 25.4 7.9
Net earnings $12,901 (1) 20.2 $12,085 (2) 19.8 6.8
Net earnings per
share (Diluted) $4.55 (1) $4.15 (2) 9.6
Effective tax rate 22.9% 22.1%
-------------------- ---- ----
(1) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings per
share (diluted) is the exclusion of IPR&D of $181 million with no tax
benefit and $0.06 per share, respectively, and the exclusion of income
representing the net impact of litigation settlements in the fourth
quarter of $379 million, $229 million, and $0.08 per share, respectively.
(2) The difference between as reported earnings and as adjusted earnings
before provision for taxes on income, net earnings and net earnings per
share (diluted) is the exclusion of IPR&D of $807 million with no tax
benefit and $0.28 per share, respectively, the exclusion of the
restructuring expense of $745 million, $528 million and $0.18 per share,
respectively, the exclusion of the NATRECOR(R) intangible asset write-down
of $678 million, $441 million, and $0.15 per share, respectively, and the
exclusion of an international tax gain on restructuring of $267 million on
net earnings, and $0.09 per share.
REPORTED SALES vs. PRIOR PERIOD
-------------------------------
$MM
---
FOURTH QUARTER
--------------
% Change
-----------------------------------
2008 2007 Reported Operational (1) Currency
---- ---- -------- --------------- --------
PHARMACEUTICAL SEGMENT (2) (3)
-------------------------------
ACIPHEX/PARIET
--------------
US 140 166 -15.7% -15.7% -
Intl 134 181 -26.0% -15.5% -10.5%
WW 274 347 -21.0% -15.6% -5.4%
CONCERTA
--------
US 208 222 -6.3% -6.3% -
Intl 72 67 7.5% 34.3% -26.8%
WW 280 289 -3.1% 3.1% -6.2%
DURAGESIC/FENTANYL TRANSDERMAL
------------------------------
US 72 72 0.0% 0.0% -
Intl 200 192 4.2% 10.4% -6.2%
WW 272 264 3.0% 7.5% -4.5%
LEVAQUIN/FLOXIN
---------------
US 393 409 -3.9% -3.9% -
Intl 18 23 -21.7% -7.7% -14.0%
WW 411 432 -4.9% -4.2% -0.7%
PROCRIT/EPREX
--------------
US 318 331 -3.9% -3.9% -
Intl 242 297 -18.5% -8.2% -10.3%
WW 560 628 -10.8% -5.9% -4.9%
RAZADYNE/REMINYL
----------------
US 11 49 -77.6% -77.6% -
Intl 91 92 -1.1% 12.1% -13.2%
WW 102 141 -27.7% -19.1% -8.6%
REMICADE
--------
US 672 661 1.7% 1.7% -
US Exports (4) 209 246 -15.0% -15.0% -
Intl 5 1 400.0% 385.4% 14.6%
WW 886 908 -2.4% -2.4% -
RISPERDAL/RISPERIDONE
----------------------
US 91 570 -84.0% -84.0% -
Intl 194 304 -36.2% -33.6% -2.6%
WW 285 874 -67.4% -66.5% -0.9%
RISPERDAL CONSTA
----------------
US 117 108 8.3% 8.3% -
Intl 202 187 8.0% 20.9% -12.9%
WW 319 295 8.1% 16.3% -8.2%
TOPAMAX
-------
US 576 535 7.7% 7.7% -
Intl 104 117 -11.1% 0.9% -12.0%
WW 680 652 4.3% 6.4% -2.1%
VELCADE
-------
US - 3 -100.0% -100.0% -
Intl 208 162 28.4% 35.9% -7.5%
WW 208 165 26.1% 33.5% -7.4%
OTHER
-----
US 623 572 8.9% 8.9% -
Intl 785 830 -5.4% 3.2% -8.6%
WW 1,408 1,402 0.4% 5.5% -5.1%
TOTAL PHARMACEUTICAL
--------------------
US 3,430 3,944 -13.0% -13.0% -
Intl 2,255 2,453 -8.1% 0.5% -8.6%
WW 5,685 6,397 -11.1% -7.8% -3.3%
TWELVE MONTHS
% Change
-----------------------------------
2008 2007 Reported Operational (1) Currency
---- ---- -------- --------------- --------
PHARMACEUTICAL SEGMENT (2) (3)
-------------------------------
ACIPHEX/PARIET
--------------
US 539 645 -16.4% -16.4% -
Intl 619 712 -13.1% -16.6% 3.5%
WW 1,158 1,357 -14.7% -16.6% 1.9%
CONCERTA
--------
US 830 798 4.0% 4.0% -
Intl 417 230 81.3% 77.4% 3.9%
WW 1,247 1,028 21.3% 20.4% 0.9%
DURAGESIC/FENTANYL TRANSDERMAL
------------------------------
US 271 391 -30.7% -30.7% -
Intl 765 773 -1.0% -6.3% 5.3%
WW 1,036 1,164 -11.0% -14.5% 3.5%
LEVAQUIN/FLOXIN
---------------
US 1,510 1,564 -3.5% -3.5% -
Intl 81 82 -1.2% -1.0% -0.2%
WW 1,591 1,646 -3.3% -3.3% 0.0%
PROCRIT/EXPREX
--------------
US 1,332 1,690 -21.2% -21.2% -
Intl 1,128 1,195 -5.6% -10.5% 4.9%
WW 2,460 2,885 -14.7% -16.7% 2.0%
RAZADYNE/REMINYL
----------------
US 134 194 -30.9% -30.9% -
Intl 407 337 20.8% 15.1% 5.7%
WW 541 531 1.9% -1.7% 3.6%
REMICADE
--------
US 2,810 2,534 10.9% 10.9% -
US Exports (4) 927 792 17.0% 17.0% -
Intl 11 1 1000.0% 976.8% 23.2%
WW 3,748 3,327 12.7% 12.7% -
RISPERDAL/RISPERIDONE
----------------------
US 1,287 2,198 -41.4% -41.4% -
Intl 839 1,222 -31.3% -35.6% 4.3%
WW 2,126 3,420 -37.8% -39.3% 1.5%
RISPERDAL CONSTA
----------------
US 456 422 8.1% 8.1% -
Intl 853 706 20.8% 15.2% 5.6%
WW 1,309 1,128 16.0% 12.5% 3.5%
TOPAMAX
-------
US 2,250 2,006 12.2% 12.2% -
Intl 481 447 7.6% 3.4% 4.2%
WW 2,731 2,453 11.3% 10.5% 0.8%
VELCADE
-------
US 4 8 -50.0% -50.0% -
Intl 783 526 48.9% 42.1% 6.8%
WW 787 534 47.4% 40.7% 6.7%
OTHER
-----
US 2,481 2,361 5.1% 5.1% -
Intl 3,352 3,032 10.6% 4.0% 6.6%
WW 5,833 5,393 8.2% 4.5% 3.7%
TOTAL PHARMACEUTICAL
--------------------
US 14,831 15,603 -4.9% -4.9% -
Intl 9,736 9,263 5.1% 0.1% 5.0%
WW 24,567 24,866 -1.2% -3.1% 1.9%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Prior year amounts have been reclassified to conform with current
presentation
(4) For external purposes, reported as U.S. sales
FOURTH QUARTER
--------------
% Change
-----------------------------------
2008 2007 Reported Operational (1) Currency
---- ---- -------- --------------- --------
MEDICAL DEVICES AND DIAGNOSTICS (2) (3)
CORDIS (4)
----------
US 253 394 -35.8% -35.8% -
Intl 469 474 -1.1% 1.3% -2.4%
WW 722 868 -16.8% -15.5% -1.3%
DEPUY
-----
US 727 661 10.0% 10.0% -
Intl 525 548 -4.2% 6.2% -10.4%
WW 1,252 1,209 3.6% 8.3% -4.7%
DIABETES CARE
-------------
US 275 337 -18.4% -18.4% -
Intl 304 306 -0.7% 7.5% -8.2%
WW 579 643 -10.0% -6.1% -3.9%
ETHICON ENDO-SURGERY
--------------------
US 515 481 7.1% 7.1% -
Intl 602 583 3.3% 11.6% -8.3%
WW 1,117 1,064 5.0% 9.0% -4.0%
ETHICON (5)
-----------
US 363 353 2.8% 2.8% -
Intl 555 591 -6.1% 3.5% -9.6%
WW 918 944 -2.8% 3.3% -6.1%
ORTHO-CLINICAL DIAGNOSTICS (5)
------------------------------
US 248 245 1.2% 1.2% -
Intl 204 211 -3.3% 2.3% -5.6%
WW 452 456 -0.9% 1.7% -2.6%
VISION CARE
-----------
US 201 190 5.8% 5.8% -
Intl 401 376 6.6% 5.5% 1.1%
WW 602 566 6.4% 5.7% 0.7%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
-------------------------------------
US 2,582 2,661 -3.0% -3.0% -
Intl 3,060 3,089 -0.9% 5.6% -6.5%
WW 5,642 5,750 -1.9% 1.6% -3.5%
TWELVE MONTHS
-------------
% Change
-----------------------------------
2008 2007 Reported Operational (1) Currency
---- ---- -------- --------------- --------
MEDICAL DEVICES AND DIAGNOSTICS (2) (3)
CORDIS (4)
----------
US 1,235 1,588 -22.2% -22.2% -
Intl 1,900 1,837 3.4% -3.1% 6.5%
WW 3,135 3,425 -8.5% -12.0% 3.5%
DEPUY
-----
US 2,803 2,638 6.3% 6.3% -
Intl 2,186 1,949 12.2% 8.3% 3.9%
WW 4,989 4,587 8.8% 7.1% 1.7%
DIABETES CARE
-------------
US 1,265 1,260 0.4% 0.4% -
Intl 1,270 1,113 14.1% 7.8% 6.3%
WW 2,535 2,373 6.8% 3.9% 2.9%
ETHICON ENDO-SURGERY
--------------------
US 1,901 1,792 6.1% 6.1% -
Intl 2,385 2,042 16.8% 11.3% 5.5%
WW 4,286 3,834 11.8% 8.8% 3.0%
ETHICON (5)
-----------
US 1,450 1,399 3.6% 3.6% -
Intl 2,390 2,204 8.4% 4.0% 4.4%
WW 3,840 3,603 6.6% 3.9% 2.7%
ORTHO-CLINICAL DIAGNOSTICS (5)
------------------------------
US 997 944 5.6% 5.6% -
Intl 844 761 10.9% 5.0% 5.9%
WW 1,841 1,705 8.0% 5.4% 2.6%
VISION CARE
-----------
US 890 812 9.6% 9.6% -
Intl 1,610 1,397 15.2% 8.0% 7.2%
WW 2,500 2,209 13.2% 8.6% 4.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
-------------------------------------
US 10,541 10,433 1.0% 1.0% -
Intl 12,585 11,303 11.3% 5.8% 5.5%
WW 23,126 21,736 6.4% 3.5% 2.9%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Prior year amounts have been reclassified to conform with current
presentation
(4) Includes sales of Drug-Eluting Stents for Q4 2008 of $70, $202 and
$272 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q4 2007 of $189, $225 and
$414 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Dec YTD 2008 of $503, $852
and $1,355 million Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Dec YTD 2007 of $818, $943
and $1,761 million Domestic, International and Worldwide respectively
(5) Prior year amounts include sales previously reported as "other"
FOURTH QUARTER
--------------
% Change
-----------------------------------
2008 2007 Reported Operational (1) Currency
---- ---- -------- --------------- --------
CONSUMER SEGMENT (2)
---------------------
SKIN CARE
---------
US 343 323 6.2% 6.2% -
Intl 501 470 6.6% 15.3% -8.7%
WW 844 793 6.4% 11.5% -5.1%
BABY CARE
---------
US 109 116 -6.0% -6.0% -
Intl 414 421 -1.7% 5.7% -7.4%
WW 523 537 -2.6% 3.2% -5.8%
ORAL CARE
---------
US 192 189 1.6% 1.6% -
Intl 204 190 7.4% 19.3% -11.9%
WW 396 379 4.5% 10.5% -6.0%
OTC/NUTRITIONALS
----------------
US 762 728 4.7% 4.7% -
Intl 694 687 1.0% 12.6% -11.6%
WW 1,456 1,415 2.9% 8.5% -5.6%
WOMEN'S HEALTH
--------------
US 148 148 0.0% 0.0% -
Intl 288 313 -8.0% 1.6% -9.6%
WW 436 461 -5.4% 1.1% -6.5%
WOUND CARE / OTHER
------------------
US 101 122 -17.2% -17.2% -
Intl 99 103 -3.9% 7.0% -10.9%
WW 200 225 -11.1% -6.1% -5.0%
TOTAL CONSUMER
--------------
US 1,655 1,626 1.8% 1.8% -
Intl 2,200 2,184 0.7% 10.6% -9.9%
WW 3,855 3,810 1.2% 6.9% -5.7%
TWELVE MONTHS
-------------
% Change
-----------------------------------
2008 2007 Reported Operational (1) Currency
---- ---- -------- --------------- --------
CONSUMER SEGMENT (2)
---------------------
SKIN CARE
---------
US 1,462 1,329 10.0% 10.0% -
Intl 1,919 1,722 11.4% 6.7% 4.7%
WW 3,381 3,051 10.8% 8.1% 2.7%
BABY CARE
---------
US 449 444 1.1% 1.1% -
Intl 1,765 1,538 14.8% 10.1% 4.7%
WW 2,214 1,982 11.7% 8.0% 3.7%
ORAL CARE
---------
US 780 789 -1.1% -1.1% -
Intl 844 699 20.7% 17.1% 3.6%
WW 1,624 1,488 9.1% 7.4% 1.7%
OTC/NUTRITIONALS
----------------
US 3,061 2,620 16.8% 16.8% -
Intl 2,833 2,522 12.3% 8.2% 4.1%
WW 5,894 5,142 14.6% 12.6% 2.0%
WOMEN'S HEALTH
--------------
US 618 623 -0.8% -0.8% -
Intl 1,293 1,183 9.3% 4.1% 5.2%
WW 1,911 1,806 5.8% 2.4% 3.4%
WOUND CARE / OTHER
------------------
US 567 603 -6.0% -6.0% -
Intl 463 421 10.0% 4.8% 5.2%
WW 1,030 1,024 0.6% -1.5% 2.1%
TOTAL CONSUMER
--------------
US 6,937 6,408 8.3% 8.3% -
Intl 9,117 8,085 12.8% 8.3% 4.5%
WW 16,054 14,493 10.8% 8.3% 2.5%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
SOURCE Johnson & Johnson
http://www.investor.jnj.com
Copyright © 2009 PR Newswire. All rights reserved